Valneva SE, a prominent player in the biotechnology sector, has been making significant strides in the development and commercialization of vaccines targeting a range of infectious diseases. As of July 31, 2026, the company, headquartered in Nantes, France, continues to focus on its core mission of addressing global health challenges through innovative vaccine solutions.
Valneva SE’s portfolio includes IXIARO/JESPECT, a vaccine designed for the prevention of Japanese encephalitis, and Dukoral, which is indicated for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli, primarily targeting travelers. These products underscore the company’s commitment to addressing infectious diseases that pose significant risks to public health.
In addition to its marketed vaccines, Valneva SE is actively developing vaccines for several other infectious diseases, including Clostridium difficile, Lyme disease, Chikungunya, and Zika. These efforts highlight the company’s proactive approach to expanding its vaccine offerings and addressing emerging health threats.
A key aspect of Valneva SE’s strategy is its collaboration with biopharmaceutical and pharmaceutical companies, as well as academic institutions. Through these partnerships, the company leverages its proprietary EB66 vaccine production cell line and IC31 adjuvant, which are integral to its vaccine development technologies. These collaborations not only enhance Valneva SE’s research capabilities but also facilitate the advancement of its vaccine candidates.
Financially, Valneva SE has experienced fluctuations in its stock performance. As of July 29, 2026, the company’s close price stood at 2.165 EUR, with a 52-week high of 5.415 EUR recorded on August 17, 2025, and a 52-week low of 2.033 EUR on July 23, 2026. The company’s market capitalization is currently valued at 454.64 million EUR. Despite a negative price-to-earnings ratio of -2.81, Valneva SE remains a significant entity within the biotechnology sector, listed on the NYSE Euronext Paris.
Since its initial public offering on June 29, 2007, Valneva SE has established itself as a key player in the vaccine industry, with operations spanning multiple countries. The company’s ongoing efforts to innovate and expand its vaccine portfolio position it well to address future public health challenges.
For more information, Valneva SE maintains an active online presence through its website, www.valneva.com , where stakeholders can access detailed insights into its operations, research initiatives, and strategic partnerships. As Valneva SE continues to navigate the dynamic landscape of the biotechnology sector, its focus on developing vaccines for infectious diseases remains a cornerstone of its mission to improve global health outcomes.
